Skip Navigation LinksHome > November 2013 - Volume 21 - Issue 6 > Virological Response to Standard- and Double-Dose Oseltamivi...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31828bbb66
Original Articles

Virological Response to Standard- and Double-Dose Oseltamivir Treatment in Patients With Pandemic (H1N1) 2009 Influenza: A Prospective Randomized Trial

Durigon, Edison L. PhD*; Thomazelli, Luciano M. PhD*; Oliveira, Danielle B.L. PhD*; Macedo, Priscila V. BSc*; Lotufo, João P.B. MSc; da Cunha, Clóvis A. MD; Neto, João T. PhD§

Collapse Box

Abstract

Background

In the early stages of the 2009 influenza pandemic, little was known about the pandemic (H1N1) 2009 virus or its response to neuraminidase inhibitor therapy.

Methods

Between April 2009 and August 2010, we conducted an open-label study of the response to oseltamivir therapy when administered at the recommended dose or at double the recommended dose twice daily for 5 days.

Results

Thirty-eight patients aged 5 years or older with laboratory-confirmed pandemic (H1N1) 2009 influenza were randomly assigned to treatment. After 5 days, substantial reductions in viral load and clinical signs and symptoms of influenza were observed in the standard- and double-dose groups relative to baseline values. The double-dose regimen did not provide additional benefit over the standard-dose regimen. No resistant viruses were detected. Both regimens were well tolerated, and no serious adverse events were reported.

Conclusions

Standard- and double-dose oseltamivir regimens were well tolerated in this patient group.

Copyright © 2013 by Lippincott Williams & Wilkins

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.